Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

NCT01369069 · View on ClinicalTrials.gov ↗

Study Summary

The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial is a multicenter, randomized, controlled clinical trial of 1400 patients that will include approximately 60 enrolling sites. The study hypotheses are that treatment of hyperglycemic acute ischemic stroke patients with targeted glucose concentration (80mg/dL - 130 mg/dL) will be safe and result in improved 3 month outcome after stroke.

Interventions

  • DRUG IV insulin to maintain target glucose concentration of 80-130 mg/dL
  • DRUG Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL

Study Locations (20)

California

  • Long Beach Memorial Medical Center — Long Beach
  • Ronald Regan Medical Center — Los Angeles
  • San Francisco General Hospital — San Francisco
  • California Pacific Medical Center - Davies Campus — San Francisco
  • California Pacific Medical Center-Pacific Campus — San Francisco
  • UCSF Medical Center — San Francisco
  • Stanford University Medical Center — Stanford

Georgia

  • Emory University Hospital - Midtown — Atlanta
  • Emory University Hospital — Atlanta
  • Grady Memorial Hospital — Atlanta
  • Augusta University Medical Center — Augusta

Arizona

  • University of Arizona Medical Center - South Campus — Tucson
  • University of Arizona — Tucson

Florida

  • Mayo Clinic Jacksonville — Jacksonville
  • Jackson Memorial Hospital — Miami

Illinois

  • Northwestern Memorial Hospital — Chicago
  • OSF Saint Francis Medical Center — Peoria

District of Columbia

  • MedStar Washington Hospital Center — Washington D.C.

Iowa

  • University of Iowa Hospitals & Clinics — Iowa City

Kansas

  • University of Kansas Medical Center — Kansas City

Trial Details

FieldValue
Enrollment Target 1,151 participants
Start Date 2012-04
Est. Completion 2018-11-19
Phase Phase 3

Sponsor

University of Virginia

392 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01369069

The ClinicalTrials.gov registry entry for NCT01369069 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 392 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions — of which IV insulin to maintain target glucose concentration of 80-130 mg/dL is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01369069 reports 20 study locations spanning 8 distinct geographic areas — top geographies include California, Georgia, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01369069 about?

NCT01369069 is a clinical study titled "Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial". The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial is a multicenter, randomized, controlled clinical trial of 1400 patients that will include approximately 60 enrolling sites. The study hypotheses are that treatment of hyperglycemic acute ischemic stroke patients with targeted glucose con...

What is the current status of trial NCT01369069?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,151 participants. The study started on 2012-04. Estimated completion is 2018-11-19.

What conditions does trial NCT01369069 study?

This clinical trial studies the following conditions: Diabetes, Hyperglycemia, Acute Ischemic Stroke. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01369069?

The interventions under investigation include: IV insulin to maintain target glucose concentration of 80-130 mg/dL (DRUG), Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01369069?

This trial is sponsored by University of Virginia, which has 392 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01369069 being conducted?

This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial